Peter Schoevers and Henk Viëtor founded DDF in 2003. Since then the company has expanded and the DDF group companies now include several synergistic organizations. The DDF Ventures Fund supports DDF’s portfolio companies. Catalyze is helping life science companies througout Europe to secure non-dilutive funding. Julius Clinical is a large, internationally operating CRO with strong academic roots.
Henk Viëtor is a medical doctor and scientists by training, specialized in (clinical) immunology, transfusion medicine and clinical genetics. His scientific results were published in numerous leading scientific journals including Nature. He is inventor on several patents. He has been an active entrepreneur in the industry and is co-founder of more than 20 (Life Sciences) spin-off companies. He is on the board of the Center for Translational Medicine.
Peter Schoevers has a degree in Business Administration from the University of Groningen, the Netherlands. In Japan he completed a full-time post-doctoral program. Peter Schoevers worked for Solvay Pharmaceuticals for eleven years in the Netherlands, UK, Germany, Belgium and Japan. In his last position, he was director of operations for Solvay Pharmaceuticals in Japan. His experience covers international R&D strategy and licensing deals worth several billion dollars.?Since 2000, he is an entrepreneur in the life sciences industry, and (co)founder of more than 20 companies. Peter is the CEO of Julius Clinical.